Age-related macular degeneration
Conditions
Interventions
Eylea(aflibercept)
Sponsors
Dokkyo Medical University, Koshigaya Hospital Department of Ophthalmology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) BCVA:0.1-1.0 2) naive AMD with subfoveal fluid on fluorescent angiography, indocyanine green angiography and/or optical coherence tomography 3) Willingness to provide written informed consent 4) outpatients
Exclusion criteria
Exclusion criteria: 1) Patients with any previous history of treatment of other retinal diseases with pharmacologic agents including verteporfin photodynamic therapy, aflibercept, ranibizumab, bevacizumab or steroids. 2) Clinically significant drug allergy. 3) History of vitrectomy or glaucoma surgery. 4) Presence of RPE tears, angoid streaks or pathologic myopia. 5) Concomitant conditions/diseases including uncontrolled glaucoma and intraocular inflammation 6) Patients who the doctor in charge judges are ineligible for the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The change of the amplitude of the focal macular ERG at the 12 month from baseline. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Change of BCVA at the 12 month. 2. Change of the amplitude of the focal macular ERG at the 3,6 and 12 month. 3. Change of the retinal thickness evaluated by SD-OCT at the 12 month. 4. Correlation between the focal macular ERG amplitude and BCVA. 5. Correlation between the focal macular ERG amplitude and retinal thickness. | — |
Countries
Japan
Contacts
Public ContactShigeki Machida
Dokkyo Medical University, Koshigaya Hospital Department of Ophthalmology
Outcome results
None listed